BiotechTube

Intravitreal aflibercept injection [IAI] + Sham

Phase 3Completed
0 watching 0 views this week📈 Rising
76
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Nonproliferative Diabetic Retinopathy

Conditions

Nonproliferative Diabetic Retinopathy

Trial Timeline

Mar 29, 2016 → Jul 16, 2019

NCT ID
NCT02718326

About Intravitreal aflibercept injection [IAI] + Sham

Intravitreal aflibercept injection [IAI] + Sham is a phase 3 stage product being developed by Regeneron Pharmaceuticals for Nonproliferative Diabetic Retinopathy. The current trial status is completed. This product is registered under clinical trial identifier NCT02718326. Target conditions include Nonproliferative Diabetic Retinopathy.

Hype Score Breakdown

Clinical
27
Activity
18
Company
9
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT02718326Phase 3Completed

Competing Products

3 competing products in Nonproliferative Diabetic Retinopathy

See all competitors
ProductCompanyStageHype Score
LucentisNovartisApproved
85
EYP-1901EyePoint PharmaceuticalsPhase 2
47
AKB-9778 + PlaceboEyePoint PharmaceuticalsPhase 2
47

Other Products from Regeneron Pharmaceuticals

DupilumabApproved
84
Intravitreal Aflibercept Injection 2mgApproved
84
Intravitreal aflibercept injection 2.0mgApproved
84
PozelimabApproved
84
DupilumabApproved
84